Clinical Trial

LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2017-08-17; most recent amendment 2025-09-14.
Status change: Not Yet Recruiting → Enrolling by Invitation 2019-11-19
Trial Details
NCT Number NCT03254667
Lead Sponsor Bausch Health Americas, Inc.
Conditions Psoriasis
Enrollment 3,500 participants
Start Date 2017-07-25
Primary Completion 2030-11-10 (estimated)
Study Completion 2031-11 (estimated)
Updated on ClinicalTrials.gov 2025-09-16